ESMO 2023 | Utilizing novel biomarkers as treatment personalization tools in colorectal cancer

Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses various biomarkers that will help to determine disease prognosis and allow for the development of personalized treatment strategies for patients with colorectal cancer. Dr Pietrantonio elaborates on some associated trials which have found these biomarkers to be of relevance. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.